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Abstract
Cardiac tumours are benign or malignant neoplasms arising primarily in the inner lining, muscle
layer, or the surrounding pericardium of the heart. They can be primary or metastatic. Primary
cardiac tumours are rare in paediatric practice with a prevalence of 0.0017 to 0.28 in autopsy
series. In contrast, the incidence of cardiac tumours during foetal life has been reported to be
approximately 0.14%. The vast majority of primary cardiac tumours in children are benign, whilst
approximately 10% are malignant. Secondary malignant tumours are 10–20 times more prevalent
than primary malignant tumours. Rhabdomyoma is the most common cardiac tumour during foetal
life and childhood. It accounts for more than 60% of all primary cardiac tumours. The frequency
and type of cardiac tumours in adults differ from those in children with 75% being benign and 25%
being malignant. Myxomas are the most common primary tumours in adults constituting 40% of
benign tumours. Sarcomas make up 75% of malignant cardiac masses. Echocardiography,
Computing Tomography (CT) and Magnetic Resonance Imaging (MRI) of the heart are the main
non-invasive diagnostic tools. Cardiac catheterisation is seldom necessary. Tumour biopsy with
histological assessment remains the gold standard for confirmation of the diagnosis. Surgical
resection of primary cardiac tumours should be considered to relieve symptoms and mechanical
obstruction to blood flow. The outcome of surgical resection in symptomatic, non-myxomatous
benign cardiac tumours is favourable. Patients with primary cardiac malignancies may benefit from
palliative surgery but this approach should not be recommended for patients with metastatic
cardiac tumours. Surgery, chemotherapy and radiotherapy may prolong survival. The prognosis for
malignant primary cardiac tumours is generally extremely poor.
Definition, epidemiology and diagnosis
Cardiac tumours are benign or malignant neoplasms aris-
ing primarily in the inner lining, muscle layer, or the sur-
rounding pericardium of the heart. Cardiac tumours can
be primary or metastatic. Primary cardiac tumours are rare
in paediatric practice with a prevalence of 0.0017 to 0.28
in autopsy series. In contrast, the incidence of cardiac
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tumours during fetal life has been reported to be approxi-
mately 0.14% [1-3].
The vast majority of primary cardiac tumours in children
are benign, whilst approximately 10% are malignant. Sec-
ondary malignant tumours are 10–20 times more preva-
lent than primary malignant tumours [4]. The frequency
and type of cardiac tumours in adults differ from children
with 75% being benign and 25% being malignant. Myxo-
mas are the most common primary tumours in adults
constituting 40% of benign tumours. Sarcomas make up
75% of malignant cardiac masses [5,6].
Rhabdomyoma is the most common cardiac tumour dur-
ing fetal life and childhood (Table 1). This is usually fol-
lowed by teratoma, fibroma and haemangioma [3].
Myxoma is exceedingly rare in foetuses and neonates
[4,7]. Likewise, fibroma and intracardiac teratoma are
exceptionally rare in adults but more commonly seen in
the first year of life during childhood. Rhabdomyoma and
pericardial teratoma make up more than 70% of the pri-
mary tumours of the heart in foetuses, neonates, and
infants [8,9].
Cardiac tumours may present in foetal or post-natal life.
The presenting features depend on the size and location of
the mass. In the foetus a tumour can be noted on a routine
antenatal anomaly scan as an intracardiac mass. The man-
ifestations of a cardiac tumour in foetal life include
arrhythmia, congestive heart failure, hydrops, and not
infrequently stillbirth. In postnatal life cardiac tumours
may affect the integrity and function of the adjacent car-
diac structures leading to severely compromised blood
flow due to inflow (Figure 1) or outflow tract obstruction
(Figure 2), cyanosis, murmur, respiratory distress, myo-
cardial dysfunction, valvular insufficiency, arrhythmias,
and sudden death [2,8].
The diagnosis of cardiac tumours can be established in
symptomatic patients, but in rare cases sudden death is
the presenting feature. Echocardiography or Magnetic Res-
onance Imaging (MRI) is usually adequate to facilitate the
diagnosis of cardiac tumours. Cardiac catheterisation is
rarely necessary. Tumour biopsy, with histological assess-
ment, remains as the gold standard for confirmation of
the diagnosis.
Due to the progressive nature of pregnancy, fetal cardiac
tumours are expected to grow antenatally and it is not
unusual for cardiac lesions to be missed at an early obstet-
ric scan. Some tumours can be detected from 20 weeks
onwards but the majority will develop later in the course
of the pregnancy (Figure 3). Most fetal cardiac tumours
will be readily detectable in the late second or third tri-
mester [3,8].
Benign cardiac tumours
Rhabdomyoma
The most common primary cardiac tumour in infants and
children is rhabdomyoma. It accounts for more than 60%
of all primary cardiac tumours [6,7]. Rhabdomyomas are
usually located within the ventricles but not infrequently
they may also originate in the atriums. Their location in
the atrioventricular junction may have a rather peculiar
effect where tumour may act like an accessory pathway
with resultant pre-excitation on twelve lead electrocardio-
gram (ECG).
Fetal diagnosis of cardiac rhabdomyoma is most com-
monly made on a 20-week anomaly scan after incidental
detection of multiple intracardiac masses. Occasionally,
cardiac rhabdomyoma may be noted coincidentally dur-
ing evaluation for fetal cardiac arrhythmia.
Although the association of multiple cardiac rhabdomyo-
mas with tuberous sclerosis has long been recognised, the
association with a single rhabdomyoma is not clear. How-
ever, in case of a solitary tumour a careful examination of
cardiac chambers should be made in order not to miss
smaller lesions elsewhere. Multiple cardiac rhabdomyo-
mas in fetal life may herald the diagnosis of tuberous scle-
rosis well before the other features of the disease, such as
skin signs or seizures, emerge in infancy [10,11]. The inci-
dence of tuberous sclerosis in patients with cardiac rhab-
domyoma has been reported to be between 60–80%
[12,13].
Equally in patients with the diagnosis of tuberous sclero-
sis, cardiac rhabdomyoma can be detected between 43–
72% of cases and their presence may assist in making a
definitive diagnosis of the condition [10,11]. However,
the diagnosis of tuberous sclerosis must only be made on
the basis of strict criteria, and the presence of multiple car-
diac rhabdomyomas, whilst raising strong suspicions, is
not by itself sufficient evidence to establish the diagnosis.
Nevertheless, detection of multiple cardiac tumours
should raise a strong suspicion of rhabdomyoma, hence
tuberous sclerosis. In such patients a detailed family his-
tory should be obtained and genetic counselling should
be offered [14].
After birth, symptoms are commonly related to obstruc-
tion of inflow or outflow tracts (Figures 4 and 5).
Clinical examination may reveal a murmur, reduced
peripheral pulses or cyanosis. Arrhythmias are not a rare
event and have been reported to occur in 16 to 47% of
cases with cardiac rhabdomyoma. Atrial or ventricular
arrhythmias frequently occur but a higher incidence of
Wolff-Parkinson-White syndrome has been noted in
patients with tuberous sclerosis (1.5%) compared to theOrphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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general population (0.15%). This may be explained by
the fact that the tumour cells may create continuity at the
atrioventricular junction between the atrial and ventricu-
lar myocardium. Since the tumour cells are structurally
similar to Purkinje cells they can function like accessory
pathways [15]. As the tumour regresses, the associated
arrhythmias also undergo spontaneous resolution and
loss of the delta wave is frequently encountered [16] (Fig-
ures 6 and 7).
Macroscopically rhabdomyomas appear uniform, round
and solid, and are brighter than the neighbouring healthy
myocardium. Their predominant location is the ventricu-
lar myocardium, but they can also be seen in the atrial
wall. Rhabdomyomas are most commonly multiple and
intracavitary extensions are found in up to 50% of
patients. Echocardiography is diagnostic and shows mul-
tiple bright intramural masses with luminal extensions
(Figure 8).
Microscopically each tumour shows pathognomonic spi-
der cells with centrally placed cytoplasm containing the
nucleus and myofibrils radiating to the cell wall. Rhab-
domyomas are not considered to be true tumours and
many authors would describe them as hamartomas of stri-
ated muscular fibres occurring solely in the heart [17].
Rhabdomyomas exhibit immunoreactivity with the mus-
cle markers desmin, actin, myoglobin, vimentin, and also
with hamartin and tuberin. Immunohistochemical stud-
ies showed that the spider cells exhibit immunoreactivity
with ubiquitin. The ubiquitin pathway is associated with
the degradation of myoflaments, progression of cytoplas-
mic vacuolisation with the formation of spider cells,
enlargement of glycogen vacuoles, apoptosis, myxoid
degeneration and regression of the rhabdomyomas. These
above events may provide plausible explanation for the
spontaneous regression of rhabdomyomas [18]. The out-
come of antenatally detected cardiac rhabdomyomas is
favourable. Once foetal somatic growth is completed,
hamartomas lose their mitotic potential and undergo
apoptosis [19]. The majority of tumours will regress
towards the end of the third trimester although rarely
some may continue to grow larger. Despite the expected
shrinkage of these tumours, unexpected foetal loss may
occur due to arrhythmias or obstruction of blood flow.
After birth, rhabdomyoma cells lose their ability to divide
and regression of the tumour in infancy is an expected
outcome, regardless of size of the tumour [20-22]. Hence,
following birth, tumour regression is a rule rather than an
exception. Complete resolution of more than 80% of the
tumours may occur during early childhood [23].
Thus, due to high rate of spontaneous regression, after
birth these tumours can be managed conservatively with
echocardiography and ECG monitoring. Surgical inter-
vention should be preserved only for sick patients with
symptoms of severe obstruction with haemodynamic
compromise or haemodynamically significant and intrac-
table arrhythmias that are unresponsive to antiarrhythmic
drugs [24,25].
Fibroma
Fibromas are solitary tumours that are mainly located in
the ventricular septum. Fibromas are derived from con-
nective tissue fibroblasts. They are primarily seen in child-
hood and the size may vary from 1 to 10 cm. Fibroma may
Table 1: Frequency Distribution of Cardiac Tumours in Children
Primary Benign Frequency (%)
Rhabdomyoma 40-60
Teratoma 15-19
Fibroma 12-16
Myxoma 2-4
Haemangioma 5
Lymphangioma }
Haemangiopericytoma } Very rate
Oncocytic tumours }
Primary Malignant
Rabdomyosarcomas 2
Fibrosarcoma 2
Secondary Metastatic tumours
Neuroblastoma }
Leukaemia } very
Lymphoma } rare
Melanoma }
A foetal tumour in the left ventricular (LV) cavity causing LV  outflow tract obstruction Figure 1
A foetal tumour in the left ventricular (LV) cavity causing LV 
outflow tract obstruction.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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invade the ventricular muscle, replace the working myo-
cardium and may result in intractable congestive heart
failure or cyanosis. Not infrequently, a fibroma may
extend into the ventricular conduction system and can
cause ventricular arrhythmias [26-28].
Macroscopically, a fibroma is clearly demarcated from the
myocardium, but interdigitations with the surrounding
myocardium can be seen on microscopy (Figures 9 and
10). Calcification of the central portion of the tumour is
pathognomonic for fibroma reflecting poor blood supply
to the mass [29].
Cardiac fibromas usually remain dormant and spontane-
ous regression rarely occurs, therefore total surgical resec-
tion is normally recommended. Large tumours can be
resected subtotally. If progressive loss of working myocar-
dial fibres continues and cardiac failure does not resolve
following tumour resection, heart transplantation may be
considered [30,31].
Teratoma
Cardiac teratoma is a rare tumour of the heart and pericar-
dium [32]. Teratomas are the second most common
tumour in the fetus and neonate after rhabdomyoma [33-
36]. Most commonly, these tumours are detected in the
pericardial cavity attached to the pulmonary artery and
aorta [37] (Figure 11). The tumour size within the heart
varies from 2 to 9 cm in diameter, and intrapericardial
tumours as large as 15 cm have been reported [37,38]. Int-
racardiac tumours arise from the atrial or ventricular wall
as nodular masses protruding into the cardiac chambers.
Cardiac and pericardial teratomas are easily detected in
Right ventricular (RV) tumour in a 2-year-old child resulting in RV outflow tract obstruction Figure 2
Right ventricular (RV) tumour in a 2-year-old child resulting in RV outflow tract obstruction. The Doppler velocity is 2.77 m/
sec.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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Multiple rhabdomyomas are found on a foetal ultrasound at 20 weeks of gestation Figure 3
Multiple rhabdomyomas are found on a foetal ultrasound at 20 weeks of gestation. Rhabdomyomas appears brighter than the 
surrounding myocardium.
A tumour in the RV cavity results in RV midcavity obstruc- tion Figure 4
A tumour in the RV cavity results in RV midcavity obstruc-
tion.
Rhabdomyoma on the tricuspid valve with some inflow  obstruction in a different patient Figure 5
Rhabdomyoma on the tricuspid valve with some inflow 
obstruction in a different patient.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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the fetus and neonate by two-dimensional echocardiogra-
phy as heterogeneous and encapsulated cystic masses.
The main clinical findings in the foetus or neonate relate
to the mass effect of the tumour and to the accumulation
of fluid in the pericardial space (Figure 12). Fetal hydrops
and stillbirth may occur. Respiratory distress, cyanosis,
and congestive heart failure are predominant signs in the
neonate. Pericardial effusion may lead to cardiac com-
pression and tamponade. The pericardial effusion is usu-
ally serous and contains small numbers of mesothelial
cells [39].
Macroscopically teratomas have a typical cystic and mul-
tilobulated appearance (Figure 13).
Teratomas histologically contain multiple immature ele-
ments including epithelium, neuroglial tissue, thyroid,
pancreas, smooth and skeletal muscle, cartilage and bone
(Figure 14).
Although teratomas have been considered to be benign,
tumour recurrence after resection or malignant differenti-
ation has been reported. Most intrapericardial teratomas
can be easily dissected off from the great vessels; on the
contrary, surgical removal of intracardiac ones is techni-
cally more difficult [40].
Myxoma
Myxoma is the most common primary cardiac tumour in
adults (65%) with particular predilection to females [41].
The left atrium is the most common location (90%) but
they can be seen on the right atrium as well [5]. In 90% of
cases the myxoma is solitary. Myxomas usually do not
cause cardiac murmurs, but more often they present with
breathlessness, syncope, embolus, congestive heart fail-
ure, arrhythmias and constitutional symptoms. As the
presenting symptoms may not suggest a cardiac cause,
myxomas may present late in the disease and at this stage
cardiac signs may then also ensue. On occasions, left-
sided myxomas may cause diastolic murmurs or added
sounds ("diastolic plop") due to inflow obstruction.
Right-sided myxomas are rare and they may lead to tricus-
pid or pulmonary artery obstruction or pulmonary embo-
lism.
Familial occurrence of myxomas has been reported, usu-
ally seen in younger patients [42]. These myxomas are
associated with multiple endocrine syndromes including
LAMB (lentigines, atrial myxoma, mucocutaneous
myxoma, and blue naevi) and NAME (naevi, atrial
myxoma, myxoid neurofibromata, and ephelides). Famil-
ial tumours are predominantly multiple but the sporadic
cases are mostly solitary. Screening of first-degree relatives
cases of multiple myxomas should therefore be consid-
ered.
Macroscopically, myxomas are pedunculated with a short,
broad-based attachment to the atrial wall. They are gelati-
nous in consistency. The echocardiographic appearance of
a myxoma is highly suggestive of the diagnosis: it has a
pedicle, with irregular, non-homogenous small lucencies
or calcifications on it and the location is characteristically
to the atrial septum, around foramen ovale [43-45]. In
contrast, an intracardiac thrombus is usually homoge-
nous in appearance.
The treatment of choice is complete surgical excision of
the myxoma with removal of substantial portion of
healthy adjacent endocardial tissue. If the surrounding tis-
sue along with the myxoma is not resected completely, the
tumour is likely to recur. Prognosis following surgery is
quite good, albeit with a recurrence rate of up to a 5% if
there has been inadequate resection, intraoperative
implantation, tumour embolisation, or unrecognised
multiple lesions [46,47]. Survival after surgery has been
reported to be excellent with no late deaths attributable to
surgery or to myxoma recurrence during 16 years of follow
up [48].
Haemangioma
Haemangioma is an exceedingly rare tumour and can be
located anywhere within the cardiac layers with slight pre-
dilection to the ventricular septum and right atrium
[49,50]. Macroscopically, haemangiomas are subendocar-
dial nodules measuring 2–4 cm in diameter. Microscopi-
cally, they may have capillary, cavernous, intramuscular
or haemangioendotheliomatous features. The presence of
multiple haemangiomas in the skin should raise suspi-
cion of a cardiac haemangioma in the neonate [51].
Haemangiomas are benign tumours and undergo sponta-
neous regression with a good prognosis. However, their
clinical course may be unfavourable in infants due to
high-output cardiac failure, haemorrhage from ruptured
vessels, and thrombocytopaenia. Ventricular tachycardia
and cardiac tamponade are not uncommon [51]. Com-
plete surgical excision may be difficult because of the vas-
cular nature of the tumour [52].
Histiocytoid nodule – oncocytic cardiomyopathy – 
Purkinje cell tumour
These hamartomatous masses differ distinctly from rhab-
domyomas. They are mostly found in infants and young
children presenting with refractory arrhythmias or sudden
unexpected death. They have a predilection to the female
sex. These masses have been described with a variety of
names such as infantile histiocytic cardiomyopathy, onco-
cytic cardiomyopathy, histiocytoid cardiomyopathy,Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
Page 7 of 14
(page number not for citation purposes)
Purkinje cell tumour, focal lipid cardiomyopathy, and idi-
opathic infantile cardiomyopathy [53,54].
The most common clinical presentation is refractory
arrhythmias such as ventricular fibrillation, ventricular
tachycardia, and junctional tachycardia [55-58]. Prema-
A 24-hour Holter on a child a month after birth shows pre-excitation and premature atrial beats Figure 6
A 24-hour Holter on a child a month after birth shows pre-excitation and premature atrial beats.
In the same child aged 3 years the 12-lead ECG reveals loss of pre-excitation but ongoing premature atrial complexes Figure 7
In the same child aged 3 years the 12-lead ECG reveals loss of pre-excitation but ongoing premature atrial complexes.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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ture ventricular contractions, supraventricular tachycar-
dia, and partial or complete atrioventricular block can
also be seen. Oncocytic cardiomyopathy is an important
cause of sudden unexpected death in infancy [59].
Macroscopically, these masses present as focal yellowish
nodules or yellow areas of discoloration composed of vac-
uolated histiocyte-like cells within the myocardium. In up
to one-third of patients the tumours may be associated
with cardiac or extracardiac anomalies such as atrial and
ventricular septal defects, hypoplastic left heart syndrome,
cleft palate, and anomalies of the eyes, skin and central
nervous system [59,60]. Their size varies from 1 to 2 mm
in diameter. The most common locations are conduction
system and the left ventricle [58].
Microscopically, these masses contain large oval cardiac
myocytes with a coarse granular pale cytoplasm (Figure
15). The cytoplasm is filled with bizarre looking mito-
chondria. The term oncocytic cardiomyopathy describes
the process of the granules (mitochondria) replacing the
working myofibrils (Figure 16). Infants with oncocytic
cardiomyopathy may show similar oncocytic cells in
other organs including the trachea, adrenal, thyroid, ante-
rior pituitary, and salivary glands [60,61].
Echocardiography may reveal nodular deposits on the
ventricular endocardium or valves [62]. If left untreated,
oncocytic cardiomyopathy may have a fatal course in
infants with multiple unresectable lesions. Some patients
Fibroma of the heart of a foetus Figure 9
Fibroma of the heart of a foetus. There is macerated myocardium.
Echocardiography on a newborn child shows multiple rhab- domyomas in both ventricles Figure 8
Echocardiography on a newborn child shows multiple rhab-
domyomas in both ventricles. In this child the diagnosis of 
tuberous sclerosis was confirmed.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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may benefit from electrophysiological studies with map-
ping and surgical excision [57,63].
Lipoma
Cardiac lipomas are rare lesions and occur exclusively in
adults. They are encapsulated subepicardial masses. They
are commonly silent but rarely may cause symptoms
including arrhythmias and atrioventricular block [64,65].
Malignant cardiac tumours
Primary malignant cardiac tumours
Up to a quarter of all cardiac tumours may exhibit some
features of malignancy. Ninety five percent of these pri-
mary malignancies are sarcomas [66], the other 5% are
lymphomas. Sarcomas are more common in adults and
most commonly located in the right atrium. These mesen-
chymal tumours show various morphologies. The clinical
course is usually aggressive with extensive local infiltra-
tion, intracavity obstruction and death.
Angiosarcoma
Angiosarcomas are the most common primary cardiac
malignancy and more common in male sex. Eighty per-
Cystic teratoma (*) attached to the aortic root (Ao) Figure 11
Cystic teratoma (*) attached to the aortic root (Ao).
The second image shows that the tumour composed of fibroblasts arranged in fascicles Figure 10
The second image shows that the tumour composed of fibroblasts arranged in fascicles.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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cent of these tumours originate in the right atrium or peri-
cardium [66,67]. Echocardiography shows a broad based
atrial mass close to the inferior vena cava with frequent
epicardial, endocardial or intracavity extensions. Local
pulmonary, pleural and mediastinal metastases are fre-
quent. Clinical findings include right-sided heart failure,
pericardial disease, pleuritic chest pain, dyspnoea, and
pericardial effusion. Some patients (10%) may present
with nonspecific symptoms such as fever, weight loss, and
malaise. The outlook is poor, and most patients die
shortly after the onset of symptoms.
Rhabdomyosarcoma
Rhabdomyosarcomas are the second most common pri-
mary malignancy of the heart. Their origin is of striated
muscle. These malignancies are most common in adult
males and can occur in any heart chamber. The most com-
mon presenting symptoms are nonspecific including
fever, anorexia, malaise, and weight loss. The symptoms
associated with pericardial disease, pleural effusion, and
embolic phenomena are also common. As compared to
angiosarcoma, diffuse pericardial involvement is not
common and the tumour rarely invades beyond the pari-
etal pericardium. The prognosis is poor [66,69].
Fibrosarcoma
Fibrosarcomas are mesenchymal tumours with fibroblas-
tic origin. These tumours can be seen within the left or
right heart chambers [66,69]. At postmortem they are usu-
ally found in multiple intracardiac sites as firm, greyish-
white small nodules. The clinical findings include heart
murmurs, nonspecific ECG changes, chest pain, fever, and
malaise. They may spread to surrounding structures [25].
The outlook is poor with death ensuing within a year of
diagnosis.
Pericardial effusion (*) and cystic teratoma (♥) in a child Figure 12
Pericardial effusion (*) and cystic teratoma (♥) in a child.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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Lymphoma
Primary lymphoma of the heart is rare and involves only
the heart or the pericardium [70]. These tumours man be
seen in various cardiac sites without any specific predilec-
tion. They may present with congestive heart failure, car-
diomegaly, or pericardial effusion and may be seen as part
of the acquired immunodeficiency syndrome [71]. Surgi-
cal resection and radiotherapy offer limited success.
Intrapericardial phaeochromocytoma
These tumours are soft, vascular and originate from auto-
nomic paraganglia. They may be found within the atrium,
in the atrial septum, in coronary, pulmonary, or aortic
locations. If the tumour can be resected, the prognosis is
favourable [72,73].
Secondary malignant (metastatic) cardiac tumours
The incidence of cardiac metastases with malignant
tumours is estimated to be approximately 1% and 20
times higher than primary malignancies of the heart
[4,74]. The most common cardiac metastases originate
from lung tumours in men and breast tumours in women.
Metastatic tumours are mostly located in the epicardial
surface of the heart.
Macroscopically carcinomatous metastatic tumours are
multiple small, discrete, and firm nodules. Carcinomas
are more frequent than sarcomatous infiltrations.
Melanoma shows a special affinity to spread to heart with
equal distribution to all four chambers [75]. Leukemias
and lymphomas may cause intramyocardial infiltration,
haemorrhagic pericardial effusion, but occasionally they
can remain asymptomatic [66,70,71,76].
The majority of metastatic tumours remain silent but
some may present with arrhythmias, cardiac failure, or
pericardial effusion.
Diagnostic methods
Echocardiography, Computing Tomography (CT) and
MRI of the heart are the main non-invasive diagnostic
tools. Open surgical or endomyocardial biopsy is only uti-
lised to reveal the histology of the lesion before surgical
resection. A thorough metastatic check should be carried
out with CT or MRI imaging before removal of malignant
cardiac tumours. A bone marrow biopsy or bone scan may
be necessary.
Treatment
Resection
Myxomas should be excised completely along with a
small rim of surrounding healthy myocardium. In view of
their potential for embolisation or valvular obstruction,
early resection of myxomas is recommended.
Surgical resection of primary cardiac tumours should only
be considered to relieve symptoms and mechanical
obstruction to blood flow. The outcome of surgical resec-
tion in symptomatic, non-myxomatous benign cardiac
tumours is favourable [77,78].
Primary cardiac malignancies may benefit from palliative
surgery but this approach cannot be recommended for
Histology of a teratoma showing multiple immature elements  in it Figure 14
Histology of a teratoma showing multiple immature elements 
in it.
Typical cystic and multi-lobular appearance of a teratoma  excised from heart Figure 13
Typical cystic and multi-lobular appearance of a teratoma 
excised from heart.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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High power microscopy showing enlarged, granular-appearing myocytes Figure 16
High power microscopy showing enlarged, granular-appearing myocytes.
Microscopically histiocytoid nodules contain large oval cardiac myocytes with coarse granular pale cytoplasm Figure 15
Microscopically histiocytoid nodules contain large oval cardiac myocytes with coarse granular pale cytoplasm.Orphanet Journal of Rare Diseases 2007, 2:11 http://www.OJRD.com/content/2/1/11
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patients with metastatic cardiac tumours. Surgery, chemo-
therapy and radiotherapy may prolong survival. The prog-
nosis for malignant primary cardiac tumours is generally
extremely poor.
Transplantation
If the resection of the tumour is not achievable in severely
symptomatic patients, orthotopic cardiac transplantation
may be considered. This treatment modality is only an
option for patients with unresectable cardiac tumours
with no evidence of metastatic involvement of the heart.
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